The 2022 Tandem Meetings | Management of patients with thalassemia who cannot undergo HSCT or gene therapy
Andreas Kulozik
• 24 Apr 2022
Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, discusses the current standard of care (SOC) for patients with thalassemia who do not have a suitable stem cell donor or cannot receive gene therapy. These patients usually receive regular transfusions with concomitant iron chelation to prevent the toxicity caused by iron overload. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
